MNTC Stock Overview
Mentice AB (publ) provides endovascular simulation technology solutions in Europe, the Middle East, and Africa; Asia and the Asia Pacific region; and the Americas.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mentice AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr36.40 |
| 52 Week High | kr71.40 |
| 52 Week Low | kr25.10 |
| Beta | 1.17 |
| 1 Month Change | 14.83% |
| 3 Month Change | -26.46% |
| 1 Year Change | -14.95% |
| 3 Year Change | -55.17% |
| 5 Year Change | n/a |
| Change since IPO | -46.15% |
Recent News & Updates
Recent updates
Mentice AB (publ) (STO:MNTC) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Feb 17
Capital Allocation Trends At Mentice (STO:MNTC) Aren't Ideal
Feb 03Mentice AB (publ)'s (STO:MNTC) Shares Climb 29% But Its Business Is Yet to Catch Up
Jan 03Is There An Opportunity With Mentice AB (publ)'s (STO:MNTC) 45% Undervaluation?
Dec 21Mentice (STO:MNTC) Will Be Hoping To Turn Its Returns On Capital Around
Oct 04Is There An Opportunity With Mentice AB (publ)'s (STO:MNTC) 42% Undervaluation?
Jan 31Mentice AB (publ) (STO:MNTC) Shares Could Be 44% Below Their Intrinsic Value Estimate
Jun 15Why Mentice AB (publ) (STO:MNTC) Could Be Worth Watching
Apr 19Mentice AB (publ)'s (STO:MNTC) Intrinsic Value Is Potentially 59% Above Its Share Price
Feb 01Is Mentice AB (publ) (STO:MNTC) Potentially Undervalued?
Nov 22Does This Valuation Of Mentice AB (publ) (STO:MNTC) Imply Investors Are Overpaying?
Oct 06Companies Like Mentice (STO:MNTC) Can Afford To Invest In Growth
Sep 03We're Not Very Worried About Mentice's (STO:MNTC) Cash Burn Rate
May 03Calculating The Intrinsic Value Of Mentice AB (publ) (STO:MNTC)
Mar 22Could The Mentice AB (publ) (STO:MNTC) Ownership Structure Tell Us Something Useful?
Feb 15Did Mentice's (STO:MNTC) Share Price Deserve to Gain 10%?
Jan 18Need To Know: Mentice AB (publ) (STO:MNTC) Insiders Have Been Buying Shares
Dec 28
Are Investors Undervaluing Mentice AB (publ) (STO:MNTC) By 20%?
Dec 07Shareholder Returns
| MNTC | SE Healthcare Services | SE Market | |
|---|---|---|---|
| 7D | -0.3% | 3.6% | -0.7% |
| 1Y | -15.0% | 30.6% | 4.4% |
Return vs Industry: MNTC underperformed the Swedish Healthcare Services industry which returned 31.1% over the past year.
Return vs Market: MNTC underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| MNTC volatility | |
|---|---|
| MNTC Average Weekly Movement | 7.7% |
| Healthcare Services Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: MNTC's share price has been volatile over the past 3 months.
Volatility Over Time: MNTC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 114 | Göran Malmberg | www.mentice.com |
Mentice AB (publ) provides endovascular simulation technology solutions in Europe, the Middle East, and Africa; Asia and the Asia Pacific region; and the Americas. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It offers software modules in the areas of acute ischemic stroke intervention, atrial septal defect and patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee intervention, carotid intervention, patient-specific simulation, coronary advanced, essential, and intermediate, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic artery embolization, radiation safety, renal denervation, renal intervention, thoracic endovascular aortic repair, transarterial chemoembolization, transseptal puncture, uterine artery embolization, peripheral angiography, and vascular trauma and cardiac rhythm management, as well as supports interventionalists to transition from transfemoral to transradial access.
Mentice AB (publ) Fundamentals Summary
| MNTC fundamental statistics | |
|---|---|
| Market cap | kr930.71m |
| Earnings (TTM) | -kr2.82m |
| Revenue (TTM) | kr275.12m |
3.4x
P/S Ratio-330.4x
P/E RatioIs MNTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNTC income statement (TTM) | |
|---|---|
| Revenue | kr275.12m |
| Cost of Revenue | kr37.23m |
| Gross Profit | kr237.90m |
| Other Expenses | kr240.71m |
| Earnings | -kr2.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 86.47% |
| Net Profit Margin | -1.02% |
| Debt/Equity Ratio | 0% |
How did MNTC perform over the long term?
See historical performance and comparison